SAN FRANCISCO and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc (Suzhou) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces the data from Phase 1 and Phase 2 clinical studies of IBI363, first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, for the treatment of "immun

In a significant policy shift, U.S. Health Secretary Robert F. Kennedy Jr. announced that COVID-19 vaccines are no longer recommended for healthy children and pregnant women. This decision, made without the customary consultation of the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices, has sparked considerable debate among health professionals.   Kennedy, alongside FDA Commissioner Marty Makary and NIH Director Jay Bhattacharya, communicated the chang

In a significant development, the U.S. Food and Drug Administration (FDA) has placed a clinical hold on Rocket Pharmaceuticals’ mid-stage gene therapy trial following the death of a patient. The trial was evaluating RP-A501, an experimental treatment for Danon disease—a rare genetic disorder affecting heart and muscle function. The patient developed capillary leak syndrome, leading to severe complications and subsequent death.    Rocket Pharmaceuticals has voluntarily paused further dosing and i

NANJING, China, May 31, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") today announced the presentation of groundbreaking clinical data from a multicenter phase Ib/II clinical trial evaluating LBL-024, an anti-PD-L1/4-1BB bispecific antibody, in combination with etoposide plus platinum-based chemotherapy for treatment-naive patients with advanced extrapulmonary neuroendocrine carcinoma (EP-NEC). The results were featured in an oral session at the 2025 American Society of

On May 28, 2025, Eli Lilly announced its acquisition of SiteOne Therapeutics, a privately held biopharmaceutical company, in a deal valued at up to $1 billion. This strategic move grants Eli Lilly access to STC-004, SiteOne’s experimental non-opioid pain treatment targeting Nav1.8 channels involved in pain signal transmission.    The acquisition aligns with Eli Lilly’s broader strategy to diversify its pain management portfolio beyond traditional opioids. STC-004 represents a novel approach, aim

STAFFORD, TX, USA and TUEBINGEN, Germany I May 31, 2025 I Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the presentation of expanded data from the ongoing Phase 1b clinical trial evaluating IMA203 PRAME cell therapy in heavily pretreated patients with metastatic melanoma. The longer follow-up of patients demonstrates a consistent and favora

– The Itovebi (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and fulvestrant alone – – The PIK3CA mutation is found in approximately 40% of HR-positive advanced breast cancers and is associated with a poor prognosis – – New data are being presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the New Engla

– First Pivotal Phase 3 Trial to Show Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care in 1L Metastatic TNBC – – Early Trend in Improvement in Overall Survival Observed – FOSTER CITY, CA, USA I May 31, 2025 I Gilead Sciences, Inc. (Nasdaq: GILD) today announced Trodelvy ® (sacituzumab govitecan-hziy) plus Keytruda ® (pembrolizumab) reduced the risk of disease progression or death by 35% (HR: 0.65) versus standard of care Keytruda plus chemotherapy

TOKYO, Japan & BASKING RIDGE, NJ, USA I May 31, 2025 I Positive results from the DESTINY-Gastric04 phase 3 trial showed ENHERTU ® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to ramucirumab plus paclitaxel in patients with second-line HER2 positive (IHC 3+ or IHC 2+/ISH+) unresectable and/or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Results will be presented today as a late-br

Initial efficacy data for Mythic’s pH-engineered cMET-directed antibody-drug conjugate (ADC) demonstrates meaningful anti-tumor activity across all cMET expression levels, histologies, and actionable genetic alterations Preliminary overall response rate (ORR) of 36% in patients with cMET low tumors, 39% in patients with cMET high tumors and 50% in tumors with EGFR mutations and cMET high/intermediate levels, with response durations of up to 8.9 months observed Preliminary data suggest the potent